Treatment of HCV infected patients and renal disease
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 0
Abstract
Hepatitis C signifies a highly prevalent infection in patients with end stage renal disease. Most frequently it is associated to glomerulonephritis, patients on hemodyalisis and renal transplants. The prevalence of HCV antibodies in hemodialysis patients varies between 5-70% depending on the geographical location of the patients. Factors associated with the prevalence of anti HCV in patients with hemodialysis include: age, blood transfusions, tattoos, use of illegal drugs, time in hemodialysis, more than two hospitalizations, treatment in multiple hemodialysis units or a kidney transplant. In some of the reported outbreaks of hepatitis in hemodialysis units, the phylogenetic analysis indicate that the transmission of HCV could relate to failures or breaches in general precautions in the management of these type of patients resulting in nosocomial transmission owed to sharing equipment or instruments employed in the hemodialysis or by transmission from professional members of the hemodialysis units. Antiviral treatment may be affected by a number of co-factors and co-morbidities, it consist mainly of non pegylated interferon or pegylated interferon. The treatment with interferon after a renal transplant is associated with an increase in the number of rejections; reason enough to recommended that treatment should be administered before the transplant.
Authors and Affiliations
David Kershenobich
Keywords
Related Articles
- EP ID EP77972
- DOI -
- Views 111
- Downloads 0
Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt
Introduction. The inactive hepatitis B surface antigen (HBsAg) carrier state is usually characterized by minimal or absent liver pathology. However, in developing countries, owing to the very early age of infection with...
Clinical decision making in acute Budd Chiari Syndro
Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension
Background. Hepatotoxicity is a major side effect of treatment with bosentan in patients with pulmonary hypertension (PH). Bosentan is metabolized by the cytochrome CYP2C9 and inhibits the bile salt export pump, which is...
Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C
Introduction. Liver disease related to chronic viral hepatitis is a major cause of morbidity and mortality in renal transplant patients. There is no agreement upon the influence of chronic hepatitis B (HBV) and hepatitis...
Serum concentrations of substance P in cholestasis
Substance P (SP) is an excitatory neuropeptide that acts via the neurokinin-1 receptor (NK-1) in the nervous system. Pruritus, a complication of cholestasis, is a nociceptive stimulus; thus, we hypothesized that cholesta...